Menu
Recruiting NCT05854303

Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction

Observational Opioid-Induced Esophageal Dysfunction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Opioid cessation, No opioid cessation.
Who it may be relevant to
Registry conditions: Opioid-Induced Esophageal Dysfunction. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Prospective Evaluation of the Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction (OIED)

Overview

The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).

Interventions

  • Behavioral Opioid cessation
    opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
  • Other No opioid cessation
    Subjects will not stop taking opioids

Primary outcome measures

  • Number of subjects to have opioid-induced esophageal dysfunction resolution [Time frame: 4 weeks]
Secondary outcome measures (3)
  • Number of subjects with dysphagia [Time frame: 4 weeks]
  • Number of subjects with chest pain [Time frame: 4 weeks]
  • Number of subjects with opioid-induced esophageal dysfunction [Time frame: 4 weeks]

Eligibility criteria

Inclusion criteria

\- Patients enrolled in the Pain Rehabilitation Center for opioid cessation, with or without esophageal symptoms.

Exclusion criteria

  • Inability to provide informed consent.
  • Patients with previous gastroesophageal surgery or pneumatic dilation.
  • Esophageal botulinum toxin injection within the prior 12 months.
  • Esophageal stricture
  • Achalasia types I and II
  • Allergy to Lidocaine or other local anesthetics
  • Subjects on anticoagulation
  • Bilateral nasal obstruction
  • Pregnancy or breast feeding

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Mayo Clinic Minnesota — Rochester

Identifiers

NCT: NCT05854303 · 23-001879

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗